FORT WORTH, Texas–( BUSINESS WIRE )–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will feature a host of innovations across its broad portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 75 years of helping people see brilliantly. Alcon will certainly host an engaging on-site program featuring events and the latest clinical presentations across contact lenses, allergy, dry eye plus more.
“For 75 years, Alcon has remained steadfast in the mission to connect industry-leading vision treatment innovations for all eye care needs and professionals who are helping patients across the world, ” said Sean Clark, General Manager, U. S. Vision Care. “We are thrilled to continue this work as industry leaders by presenting an array of exciting events and presentations at Academy, including showcasing the growth of Alcon over the particular past 75 years plus groundbreaking plans for the future. ”
Clinical Data and Research Findings in Contact Lenses and Ocular Allergies
Several research- and investigator-initiated trials supported by Alcon will be presented in the event highlighting the results of medical research around the efficacy plus performance associated with Pataday ® , PRECISION1 ® contact lenses, and some including competitive products. One notable study shows that a single dose of Pataday Once Daily Relief Extra Strength was significantly more efficacious than a single dose of Claritin^ Tablets 24-Hour in reducing ocular itching inside subjects along with allergic conjunctivitis at both 15-minute onset of action and 24-hour duration associated with action evaluations.
- Thursday, October 27
- Poster Presentation: A Comparison of the Onset of Action and Duration of Actions of Pataday ® Once Daily Relief Additional Strength in order to Claritin Pills 24-Hour in Reducing Ocular Itching within Subjects with Allergic Conjunctivitis. Presented simply by Jason Chin, OD, & Kara Quealy, MS (available for questions in Exhibit Hall H from 4: 30-6: 30 p. m. PST)
- Friday, October 28
- Poster Demonstration: Performance of Verofilcon A Daily Disposable Contact Lenses in Digital Device Users. Presented by Marc-Matthias Schulze, PhD, Dipl. Ing., et al (available for queries in Show Hall They would from 1: 00-3: 00 p. m. PST)
- Poster Presentation: Clinical Performance associated with Two Every day Disposable Toric Soft Contact Lenses – Verofilcon The Versus Etafilcon A. Presented by Mark Perry, OD, et al (available for questions inside Exhibit Hall H from 1: 00-3: 00 p. m. PST)
- Poster Display: Clinical Performance Comparison of Two Commercially Available Everyday Disposable Soft Contact Lens: Verofilcon A Versus Somofilcon A. Offered by Katherine Bickle, Z, PhD, ainsi que al (available for questions in Display Hall H from one: 00-3: 00 p. meters. PST)
Innovations in Eye Care Expand Reach of Alcon Product Offerings
To continue its efforts in the advancement of eye care, Alcon will be expanding the footprint within the vision care market with the particular announcement associated with upcoming product launches and expansions, including:
- TOTAL30 ® for Astigmatism, the much-anticipated toric lens born through the trusted Water Gradient lens technology of TOTAL30 ® sphere lens, the first and only monthly replacement Water Gradient contact lens. 1
- Following its launch in 2020 plus during COVID-19, Alcon accelerated MARLO access to help Eye Care Professionals (ECPs) better connect along with their individuals and continues to impact the vision care business with its cutting-edge digital platform. In June 2022, the company announced MARLO had achieved the particular milestone of more than one million patients enrolled. In 2023, Alcon will expand the MARLO services to provide patients with greater access to attention care.
TOTAL Portfolio x FORTUNE Brand Studios to Provide Resources with regard to ECPs to Optimize Practice Success and Patient Loyalty, Satisfaction
The Secrets to Success: Featuring Robert Herjavec plus TOTAL ® in order to include Herjavec’s personal experience as a contact lens patient and lessons learned from his career as an entrepreneur, CEO of Cyderes, and their time on ABC’s “Shark Tank, ” including how they can apply to ECPs’ businesses. The particular 1-hour occasion will include the panel discussion with leading optometrists, Drs. Pamela Lowe and Amanda Nanasy, plus Associate Consultant from top healthcare consulting firm, BSM, Barbra Dey. The event may take place in the Hilton San Diego Bayfront, Room Indigo BF.
- Thursday, Oct 27 from 6: thirty p. michael. to 7: 30 g. m. PST. Doors will open from 6 l. m. and close with 8 s. m. regarding beverages plus networking.
- Fireside chat showcasing business expert, star of “Shark Tank, ” and CEO associated with Cyderes, Robert Herjavec, plus moderator and international award-winning journalist Del Irani
- Panel discussion highlighting “your patients’ contact lens comfort, ” presented by De Irani, Dr. Pamela Lowe, Dr . Amanda Nanasy plus Barbra Dey
- Closing remarks (opportunity intended for networking inside the room from seven: 30-8: 00 p. m. )
Visit Alcon’s booth #601 for important information on Alcon’s innovative products and programs featured in this release.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the particular United States Private Securities Litigation Reform Act associated with 1995. Forward-looking statements may be identified by words such as: “anticipate, ” “intend, ” “commitment, ” “look forward, ” “maintain, ” “plan, ” “goal, ” “seek, ” “believe, ” “project, ” “estimate, ” “expect, ” “strategy, ” “future, ” “likely, ” “may, ” “should, ” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future programs and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are usually discussed in our filings with the United Says Securities plus Exchange Commission, including our Form 20-F. In particular, our own expectations could be affected by uncertainties regarding the success of our separation and spin-off through Novartis. Should one or more of these uncertainties or even risks materialize, or should underlying presumptions prove incorrect, actual results may vary materially from those anticipated. Therefore , you should not rely on any of these forward-looking statements.
Forward-looking claims in this push release speak only as of the date of its filing, plus we assume no obligation to update forward-looking statements as a result associated with new information, future occasions or otherwise.
About Alcon
Alcon helps individuals see superbly. As the worldwide leader within eye treatment with a heritage spanning over 75 many years, we offer the particular broadest profile of items to enhance sight and improve people’s lives. Our Surgical and Eyesight Care products touch the lives greater than 260 million people in more than 140 countries each year living with problems like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24, 000 associates are enhancing the quality of life through innovative products, partnerships along with Eye Treatment Professionals plus programs that advance entry to quality eyesight care. Learn more at www.alcon.com .
^Claritin is not really owned or affiliated with Alcon
References
- A02491-REP-198231-1 Outermost Surface Softness Analysis of lehfilcon The Contact Lenses and Correlation with Water Content Based upon Petrisoft Gels.
Connect with us on